APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hospital-Acquired Infections Assays

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hospital-Acquired Infections Assays Market Analysis and Forecast 2026-2032

Report ID 17415641024 March 2026192 pages

Choose your research edition.

Industry ResearchHospital-Acquired Infections Assays Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hospital-Acquired Infections Assays Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hospital-Acquired Infections Assays Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hospital-Acquired Infections Assays Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Hospital-Acquired Infections Assays Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Hospital-Acquired Infections Assays market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hospital-Acquired Infections Assays is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hospital-Acquired Infections Assays is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hospital-Acquired Infections Assays is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hospital-Acquired Infections Assays is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hospital-Acquired Infections Assays include BIOMÉRIEUX, Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, BD (Becton, Dickinson and Company), Bioscience, Inc., QIAGEN, Thermo Fisher Scientific Inc. and Meridian Bioscience, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hospital-Acquired Infections Assays, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hospital-Acquired Infections Assays, also provides the revenue of main regions and countries. Of the upcoming market potential for Hospital-Acquired Infections Assays, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hospital-Acquired Infections Assays revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hospital-Acquired Infections Assays market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hospital-Acquired Infections Assays revenue, projected growth trends, production technology, application and end-user industry.

Hospital-Acquired Infections Assays Segment by Company

BIOMÉRIEUX

Abbott

F. Hoffmann-La Roche Ltd.

Siemens Healthcare Private Limited

BD (Becton, Dickinson and Company)

Bioscience, Inc.

QIAGEN

Thermo Fisher Scientific Inc.

Meridian Bioscience, Inc.

Hologic, Inc.

Hospital-Acquired Infections Assays Segment by Type

Blood Tests

Urinalysis

Hospital-Acquired Infections Assays Segment by Application

Urinary Tract Infections

Pneumonia

Surgical Site Infections

Bloodstream Infections

Other Hospital Infections

Hospital-Acquired Infections Assays Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hospital-Acquired Infections Assays market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hospital-Acquired Infections Assays and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hospital-Acquired Infections Assays.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hospital-Acquired Infections Assays in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hospital-Acquired Infections Assays company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hospital-Acquired Infections Assays revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hospital-Acquired Infections Assays Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Blood Tests Major Player Table 3. Urinalysis Major Player Table 4. Global Hospital-Acquired Infections Assays Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Urinary Tract Infections Major Player Table 6. Pneumonia Major Player Table 7. Surgical Site Infections Major Player Table 8. Bloodstream Infections Major Player Table 9. Other Hospital Infections Major Player Table 10. Hospital-Acquired Infections Assays Industry Trends Table 11. Hospital-Acquired Infections Assays Industry Drivers Table 12. Hospital-Acquired Infections Assays Industry Opportunities and Challenges Table 13. Hospital-Acquired Infections Assays Industry Restraints Table 14. Global Hospital-Acquired Infections Assays Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Hospital-Acquired Infections Assays Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Hospital-Acquired Infections Assays Market Share by Region (2021-2026) Table 17. Global Hospital-Acquired Infections Assays Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Hospital-Acquired Infections Assays Market Share by Region (2027-2032) Table 19. Global Hospital-Acquired Infections Assays Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Hospital-Acquired Infections Assays Revenue Market Share by Players (2021-2026) Table 21. Global Hospital-Acquired Infections Assays Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Hospital-Acquired Infections Assays Key Players Headquarters & Area Served Table 23. Global Hospital-Acquired Infections Assays Players, Product Type & Application Table 24. Global Hospital-Acquired Infections Assays Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Hospital-Acquired Infections Assays by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Hospital-Acquired Infections Assays Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Hospital-Acquired Infections Assays Revenue Market Share by Type (2021-2026) Table 31. Global Hospital-Acquired Infections Assays Revenue Market Share by Type (2027-2032) Table 32. Global Hospital-Acquired Infections Assays Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Hospital-Acquired Infections Assays Revenue Market Share by Application (2021-2026) Table 36. Global Hospital-Acquired Infections Assays Revenue Market Share by Application (2027-2032) Table 37. BIOMÉRIEUX Company Information Table 38. BIOMÉRIEUX Business Overview Table 39. BIOMÉRIEUX Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. BIOMÉRIEUX Hospital-Acquired Infections Assays Product Portfolio Table 41. BIOMÉRIEUX Recent Development Table 42. Abbott Company Information Table 43. Abbott Business Overview Table 44. Abbott Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Abbott Hospital-Acquired Infections Assays Product Portfolio Table 46. Abbott Recent Development Table 47. F. Hoffmann-La Roche Ltd. Company Information Table 48. F. Hoffmann-La Roche Ltd. Business Overview Table 49. F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Product Portfolio Table 51. F. Hoffmann-La Roche Ltd. Recent Development Table 52. Siemens Healthcare Private Limited Company Information Table 53. Siemens Healthcare Private Limited Business Overview Table 54. Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Product Portfolio Table 56. Siemens Healthcare Private Limited Recent Development Table 57. BD (Becton, Dickinson and Company) Company Information Table 58. BD (Becton, Dickinson and Company) Business Overview Table 59. BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Product Portfolio Table 61. BD (Becton, Dickinson and Company) Recent Development Table 62. Bioscience, Inc. Company Information Table 63. Bioscience, Inc. Business Overview Table 64. Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 66. Bioscience, Inc. Recent Development Table 67. QIAGEN Company Information Table 68. QIAGEN Business Overview Table 69. QIAGEN Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. QIAGEN Hospital-Acquired Infections Assays Product Portfolio Table 71. QIAGEN Recent Development Table 72. Thermo Fisher Scientific Inc. Company Information Table 73. Thermo Fisher Scientific Inc. Business Overview Table 74. Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Product Portfolio Table 76. Thermo Fisher Scientific Inc. Recent Development Table 77. Meridian Bioscience, Inc. Company Information Table 78. Meridian Bioscience, Inc. Business Overview Table 79. Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 81. Meridian Bioscience, Inc. Recent Development Table 82. Hologic, Inc. Company Information Table 83. Hologic, Inc. Business Overview Table 84. Hologic, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Hologic, Inc. Hospital-Acquired Infections Assays Product Portfolio Table 86. Hologic, Inc. Recent Development Table 87. North America Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Hospital-Acquired Infections Assays Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Hospital-Acquired Infections Assays Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Hospital-Acquired Infections Assays Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Hospital-Acquired Infections Assays Revenue by Country (US$ Million) & (2027-2032) Table 101. China Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 102. China Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 103. China Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 104. China Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Hospital-Acquired Infections Assays Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Hospital-Acquired Infections Assays Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Hospital-Acquired Infections Assays Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Hospital-Acquired Infections Assays Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Hospital-Acquired Infections Assays Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Hospital-Acquired Infections Assays Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Hospital-Acquired Infections Assays Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Hospital-Acquired Infections Assays Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Hospital-Acquired Infections Assays Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Hospital-Acquired Infections Assays Image Figure 2. Global Hospital-Acquired Infections Assays Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hospital-Acquired Infections Assays Market Size Share 2021 VS 2025 VS 2032 Figure 4. Blood Tests Image Figure 5. Urinalysis Image Figure 6. Global Hospital-Acquired Infections Assays Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hospital-Acquired Infections Assays Market Size Share 2021 VS 2025 VS 2032 Figure 8. Urinary Tract Infections Image Figure 9. Pneumonia Image Figure 10. Surgical Site Infections Image Figure 11. Bloodstream Infections Image Figure 12. Other Hospital Infections Image Figure 13. Global Hospital-Acquired Infections Assays Market Size (US$ Million) & (2021-2032) Figure 14. Global Hospital-Acquired Infections Assays Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Hospital-Acquired Infections Assays Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Hospital-Acquired Infections Assays Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Hospital-Acquired Infections Assays Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hospital-Acquired Infections Assays Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Hospital-Acquired Infections Assays Revenue Market Share by Type (2021-2032) Figure 21. Global Hospital-Acquired Infections Assays Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Hospital-Acquired Infections Assays Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Hospital-Acquired Infections Assays Revenue Market Share by Application (2021-2032) Figure 24. North America Hospital-Acquired Infections Assays Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032) Figure 26. North America Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032) Figure 27. North America Hospital-Acquired Infections Assays Revenue Share by Country (2021-2032) Figure 28. United States Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Hospital-Acquired Infections Assays Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032) Figure 33. Europe Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032) Figure 34. Europe Hospital-Acquired Infections Assays Revenue Share by Country (2021-2032) Figure 35. Germany Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Hospital-Acquired Infections Assays Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032) Figure 45. China Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032) Figure 46. Asia Hospital-Acquired Infections Assays Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032) Figure 48. Asia Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032) Figure 49. Asia Hospital-Acquired Infections Assays Revenue Share by Region (2021-2032) Figure 50. Japan Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Hospital-Acquired Infections Assays Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032) Figure 58. SAMEA Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032) Figure 59. SAMEA Hospital-Acquired Infections Assays Revenue Share by Country (2021-2032) Figure 60. Brazil Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Hospital-Acquired Infections Assays Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Tests
  • Urinalysis
Applications
  • Urinary Tract Infections
  • Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections
Companies covered
  • BIOMÉRIEUX
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare Private Limited
  • BD (Becton, Dickinson and Company)
  • Bioscience, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Meridian Bioscience, Inc.
  • Hologic, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hospital-Acquired Infections Assays Market by Type
  3. 1.2.1 Global Hospital-Acquired Infections Assays Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Blood Tests
  5. 1.2.3 Urinalysis
  6. 1.3 Hospital-Acquired Infections Assays Market by Application
  7. 1.3.1 Global Hospital-Acquired Infections Assays Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Urinary Tract Infections
  9. 1.3.3 Pneumonia
  10. 1.3.4 Surgical Site Infections
  11. 1.3.5 Bloodstream Infections
  12. 1.3.6 Other Hospital Infections
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Hospital-Acquired Infections Assays Market Dynamics
  1. 2.1 Hospital-Acquired Infections Assays Industry Trends
  2. 2.2 Hospital-Acquired Infections Assays Industry Drivers
  3. 2.3 Hospital-Acquired Infections Assays Industry Opportunities and Challenges
  4. 2.4 Hospital-Acquired Infections Assays Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hospital-Acquired Infections Assays Market Perspective (2021-2032)
  2. 3.2 Global Hospital-Acquired Infections Assays Growth Trends by Region
  3. 3.2.1 Global Hospital-Acquired Infections Assays Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hospital-Acquired Infections Assays Market Size by Region (2021-2026)
  5. 3.2.3 Global Hospital-Acquired Infections Assays Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hospital-Acquired Infections Assays Revenue by Players
  2. 4.1.1 Global Hospital-Acquired Infections Assays Revenue by Players (2021-2026)
  3. 4.1.2 Global Hospital-Acquired Infections Assays Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hospital-Acquired Infections Assays Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hospital-Acquired Infections Assays Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hospital-Acquired Infections Assays Key Players Headquarters & Area Served
  7. 4.4 Global Hospital-Acquired Infections Assays Players, Product Type & Application
  8. 4.5 Global Hospital-Acquired Infections Assays Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hospital-Acquired Infections Assays Market CR5 and HHI
  11. 4.6.3 2025 Hospital-Acquired Infections Assays Tier 1, Tier 2, and Tier 3
5 Hospital-Acquired Infections Assays Market Size by Type
  1. 5.1 Global Hospital-Acquired Infections Assays Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 5.3 Global Hospital-Acquired Infections Assays Revenue Market Share by Type (2021-2032)
6 Hospital-Acquired Infections Assays Market Size by Application
  1. 6.1 Global Hospital-Acquired Infections Assays Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  3. 6.3 Global Hospital-Acquired Infections Assays Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 BIOMÉRIEUX
  2. 7.1.1 BIOMÉRIEUX Company Information
  3. 7.1.2 BIOMÉRIEUX Business Overview
  4. 7.1.3 BIOMÉRIEUX Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  5. 7.1.4 BIOMÉRIEUX Hospital-Acquired Infections Assays Product Portfolio
  6. 7.1.5 BIOMÉRIEUX Recent Developments
  7. 7.2 Abbott
  8. 7.2.1 Abbott Company Information
  9. 7.2.2 Abbott Business Overview
  10. 7.2.3 Abbott Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Abbott Hospital-Acquired Infections Assays Product Portfolio
  12. 7.2.5 Abbott Recent Developments
  13. 7.3 F. Hoffmann-La Roche Ltd.
  14. 7.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 7.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 7.3.3 F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  17. 7.3.4 F. Hoffmann-La Roche Ltd. Hospital-Acquired Infections Assays Product Portfolio
  18. 7.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 7.4 Siemens Healthcare Private Limited
  20. 7.4.1 Siemens Healthcare Private Limited Company Information
  21. 7.4.2 Siemens Healthcare Private Limited Business Overview
  22. 7.4.3 Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Siemens Healthcare Private Limited Hospital-Acquired Infections Assays Product Portfolio
  24. 7.4.5 Siemens Healthcare Private Limited Recent Developments
  25. 7.5 BD (Becton, Dickinson and Company)
  26. 7.5.1 BD (Becton, Dickinson and Company) Company Information
  27. 7.5.2 BD (Becton, Dickinson and Company) Business Overview
  28. 7.5.3 BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  29. 7.5.4 BD (Becton, Dickinson and Company) Hospital-Acquired Infections Assays Product Portfolio
  30. 7.5.5 BD (Becton, Dickinson and Company) Recent Developments
  31. 7.6 Bioscience, Inc.
  32. 7.6.1 Bioscience, Inc. Company Information
  33. 7.6.2 Bioscience, Inc. Business Overview
  34. 7.6.3 Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
  36. 7.6.5 Bioscience, Inc. Recent Developments
  37. 7.7 QIAGEN
  38. 7.7.1 QIAGEN Company Information
  39. 7.7.2 QIAGEN Business Overview
  40. 7.7.3 QIAGEN Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  41. 7.7.4 QIAGEN Hospital-Acquired Infections Assays Product Portfolio
  42. 7.7.5 QIAGEN Recent Developments
  43. 7.8 Thermo Fisher Scientific Inc.
  44. 7.8.1 Thermo Fisher Scientific Inc. Company Information
  45. 7.8.2 Thermo Fisher Scientific Inc. Business Overview
  46. 7.8.3 Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Thermo Fisher Scientific Inc. Hospital-Acquired Infections Assays Product Portfolio
  48. 7.8.5 Thermo Fisher Scientific Inc. Recent Developments
  49. 7.9 Meridian Bioscience, Inc.
  50. 7.9.1 Meridian Bioscience, Inc. Company Information
  51. 7.9.2 Meridian Bioscience, Inc. Business Overview
  52. 7.9.3 Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Meridian Bioscience, Inc. Hospital-Acquired Infections Assays Product Portfolio
  54. 7.9.5 Meridian Bioscience, Inc. Recent Developments
  55. 7.10 Hologic, Inc.
  56. 7.10.1 Hologic, Inc. Company Information
  57. 7.10.2 Hologic, Inc. Business Overview
  58. 7.10.3 Hologic, Inc. Hospital-Acquired Infections Assays Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Hologic, Inc. Hospital-Acquired Infections Assays Product Portfolio
  60. 7.10.5 Hologic, Inc. Recent Developments
8 North America
  1. 8.1 North America Hospital-Acquired Infections Assays Revenue (2021-2032)
  2. 8.2 North America Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 8.2.1 North America Hospital-Acquired Infections Assays Revenue by Type (2021-2026)
  4. 8.2.2 North America Hospital-Acquired Infections Assays Revenue by Type (2027-2032)
  5. 8.3 North America Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032)
  6. 8.4 North America Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  7. 8.4.1 North America Hospital-Acquired Infections Assays Revenue by Application (2021-2026)
  8. 8.4.2 North America Hospital-Acquired Infections Assays Revenue by Application (2027-2032)
  9. 8.5 North America Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032)
  10. 8.6 North America Hospital-Acquired Infections Assays Revenue by Country
  11. 8.6.1 North America Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hospital-Acquired Infections Assays Revenue by Country (2021-2026)
  13. 8.6.3 North America Hospital-Acquired Infections Assays Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hospital-Acquired Infections Assays Revenue (2021-2032)
  2. 9.2 Europe Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hospital-Acquired Infections Assays Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hospital-Acquired Infections Assays Revenue by Type (2027-2032)
  5. 9.3 Europe Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hospital-Acquired Infections Assays Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hospital-Acquired Infections Assays Revenue by Application (2027-2032)
  9. 9.5 Europe Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hospital-Acquired Infections Assays Revenue by Country
  11. 9.6.1 Europe Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hospital-Acquired Infections Assays Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hospital-Acquired Infections Assays Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hospital-Acquired Infections Assays Revenue (2021-2032)
  2. 10.2 China Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 10.2.1 China Hospital-Acquired Infections Assays Revenue by Type (2021-2026)
  4. 10.2.2 China Hospital-Acquired Infections Assays Revenue by Type (2027-2032)
  5. 10.3 China Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032)
  6. 10.4 China Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  7. 10.4.1 China Hospital-Acquired Infections Assays Revenue by Application (2021-2026)
  8. 10.4.2 China Hospital-Acquired Infections Assays Revenue by Application (2027-2032)
  9. 10.5 China Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hospital-Acquired Infections Assays Revenue (2021-2032)
  2. 11.2 Asia Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hospital-Acquired Infections Assays Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hospital-Acquired Infections Assays Revenue by Type (2027-2032)
  5. 11.3 Asia Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hospital-Acquired Infections Assays Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hospital-Acquired Infections Assays Revenue by Application (2027-2032)
  9. 11.5 Asia Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hospital-Acquired Infections Assays Revenue by Country
  11. 11.6.1 Asia Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hospital-Acquired Infections Assays Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hospital-Acquired Infections Assays Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hospital-Acquired Infections Assays Revenue (2021-2032)
  2. 12.2 SAMEA Hospital-Acquired Infections Assays Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hospital-Acquired Infections Assays Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hospital-Acquired Infections Assays Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hospital-Acquired Infections Assays Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hospital-Acquired Infections Assays Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hospital-Acquired Infections Assays Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hospital-Acquired Infections Assays Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hospital-Acquired Infections Assays Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hospital-Acquired Infections Assays Revenue by Country
  11. 12.6.1 SAMEA Hospital-Acquired Infections Assays Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hospital-Acquired Infections Assays Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hospital-Acquired Infections Assays Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst